The aim of this article is to review available data on the efficacy and tolerability of meloxicam, a preferential COX-2 inhibitor, in the treatment of musculoskeletal disorders or postoperative pain.

Meloxicam is also a selective COX-2 inhibitor, reducing the risk of GI side effects compared to naproxen. However, NSAIDs that are selective COX-2 inhibitors, like meloxicam, have increased ...

Older NSAIDs, like meloxicam, do not have good long-term evidence behind them for reducing serious GI complications (perforations, ulcers, and gastric bleeding), whereas COX-2 inhibitors do.

inhibitors. Meloxicam/rizatriptan is currently approved under the brand name Symbravo for the acute treatment of migraine with or without aura in adults. The product combines a COX-2 preferential ...

Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...